Bicycle Therapeutics plc (NASDAQ:BCYC) Director Buys $7,670,000.00 in Stock

Bicycle Therapeutics plc (NASDAQ:BCYC) Director Bros. Advisors Lp Baker purchased 500,000 shares of the company’s stock in a transaction on Monday, December 16th. The stock was purchased at an average cost of $15.34 per share, for a total transaction of $7,670,000.00. Following the purchase, the director now directly owns 9,995,274 shares in the company, valued at approximately $153,327,503.16. This trade represents a 5.27 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Bros. Advisors Lp Baker also recently made the following trade(s):

• On Friday, December 13th, Bros. Advisors Lp Baker acquired 985,397 shares of Bicycle Therapeutics stock. The shares were purchased at an average price of $13.76 per share, with a total value of $13,559,062.72.

Bicycle Therapeutics Stock Performance

Bicycle Therapeutics stock opened at $15.00 on Friday. The stock has a 50-day simple moving average of $22.06 and a 200 day simple moving average of $22.56. The stock has a market capitalization of $1.04 billion, a P/E ratio of -4.56 and a beta of 0.86. Bicycle Therapeutics plc has a 52 week low of $12.17 and a 52 week high of $28.67.

Bicycle Therapeutics (NASDAQ:BCYC) last issued its earnings results on Thursday, October 31st. The company reported ($0.74) EPS for the quarter, topping the consensus estimate of ($0.78) by $0.04. Bicycle Therapeutics had a negative return on equity of 27.35% and a negative net margin of 450.64%. The company had revenue of $2.68 million during the quarter, compared to the consensus estimate of $6.82 million. During the same period in the previous year, the company posted ($1.26) EPS. The firm’s revenue for the quarter was down 50.0% compared to the same quarter last year. Research analysts forecast that Bicycle Therapeutics plc will post -3.05 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms have weighed in on BCYC. HC Wainwright reduced their price target on Bicycle Therapeutics from $55.00 to $33.00 and set a “buy” rating for the company in a research report on Monday. Stephens began coverage on shares of Bicycle Therapeutics in a report on Friday, November 8th. They set an “equal weight” rating and a $25.00 target price for the company. Needham & Company LLC reiterated a “buy” rating and issued a $38.00 price target on shares of Bicycle Therapeutics in a research note on Thursday, October 31st. Cantor Fitzgerald restated an “overweight” rating on shares of Bicycle Therapeutics in a research note on Monday, September 9th. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $35.00 price objective on shares of Bicycle Therapeutics in a report on Friday, November 1st. Two investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $35.25.

Hedge Funds Weigh In On Bicycle Therapeutics

Large investors have recently modified their holdings of the stock. GAMMA Investing LLC boosted its holdings in shares of Bicycle Therapeutics by 105.1% during the 3rd quarter. GAMMA Investing LLC now owns 2,026 shares of the company’s stock worth $46,000 after buying an additional 1,038 shares during the period. L & S Advisors Inc lifted its position in Bicycle Therapeutics by 2.4% during the third quarter. L & S Advisors Inc now owns 59,735 shares of the company’s stock worth $1,352,000 after acquiring an additional 1,400 shares during the last quarter. Assetmark Inc. acquired a new stake in Bicycle Therapeutics during the third quarter worth approximately $34,000. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Bicycle Therapeutics by 69.1% during the third quarter. China Universal Asset Management Co. Ltd. now owns 7,138 shares of the company’s stock worth $162,000 after acquiring an additional 2,918 shares during the period. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its position in shares of Bicycle Therapeutics by 0.6% in the second quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 888,081 shares of the company’s stock valued at $17,975,000 after purchasing an additional 4,976 shares during the last quarter. 86.15% of the stock is owned by institutional investors.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.